Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993836 | 0.94 | TRPV4 (0.38) | TRPV4ALDH1A1SYKTSHRMAPT | |
| SCHEMBL2000181 | 0.93 | ALDH1A1 (0.38) | TRPV4ALDH1A1SYKTSHRMAPT | |
| SCHEMBL1992226 | 0.86 | ALDH1A1 (0.40) | TRPV4ALDH1A1SYKTSHRMAPT | |
| SCHEMBL1990420 | 0.75 | PDE10A (0.36) | TRPV4ALDH1A1TSHRMAOBADORA1 | |
| SCHEMBL1989787 | 0.74 | KCNH2 (0.38) | TRPV4ALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL1996912 | 0.73 | TRPV4 (0.37) | TRPV4ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1991408 | 0.73 | TRPV4 (0.34) | TRPV4ALDH1A1TSHRMAOBADORA1 | |
| SCHEMBL5442053 | 0.73 | TRPV4 (0.46) | TRPV4ALDH1A1TSHRMAPT | |
| SCHEMBL1990186 | 0.71 | CDK1 (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL11920280 | 0.71 | HKDC1 (0.37) | ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866310-B1 | 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2012-07-11 | — | — | EP | disclosed |
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-1866310-A1 | 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006100520-A1 | 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | NR2C2, NR3C2, NR2E3 | TRPV4 1580/4885ALDH1A1 1796/4885SYK 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.